Value of Gene-Based Patents in the Eye of the Beholder
By Mari Serebrov
Friday, January 11, 2013
The only thing that was clear in a roundtable discussion the Patent and Trademark Office (PTO) held Thursday on gene-based diagnostics is that a consensus on the value of patents for the diagnostics, and DNA in general, is as out of reach as ever.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.